Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with brain metastases that are ≤ 1 cm, are symptomatic, and require treatment may be eligible after discussion with Medical Monitor.
Eastern Cooperative Oncology Group performance status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights
Study Summary
This trial is testing a new drug, CX-904, to see if it is safe and effective in treating adults with metastatic or locally advanced unresectable solid tumors.
Who is the study for?
This trial is for adults with advanced solid tumors that can't be surgically removed and have spread. They should have tried standard treatments already, not have serious heart issues or autoimmune diseases, and agree to use effective birth control. Those with small, symptom-free brain metastases may join after special consideration.Check my eligibility
What is being tested?
The study tests CX-904's safety and effectiveness in treating advanced solid tumors. It will assess how the body processes the drug (PK), its impact on the tumor (PD), tolerability at different doses, and any potential benefits in shrinking or controlling tumor growth.See study design
What are the potential side effects?
Since this is a first-in-human study for CX-904, specific side effects are unknown but could include typical reactions seen with cancer drugs such as nausea, fatigue, allergic reactions, blood count changes, organ inflammation or other unexpected symptoms.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have small brain tumors (≤1 cm) that need treatment.
Select...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and I've had standard treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patients Experiencing Dose-limiting Toxicity
Secondary outcome measures
Disease Control Rate (DCR)
Duration of Response (DOR)
Investigator-assessed Progression-Free Survival (PFS)
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: CX-904Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
CytomX TherapeuticsLead Sponsor
7 Previous Clinical Trials
784 Total Patients Enrolled
Monika Vainorius, M.D.Study DirectorCytomX Therapeutics, Inc
2 Previous Clinical Trials
258 Total Patients Enrolled
Lawrence LuStudy DirectorCytomX Therapeutics, Inc
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I had cancer within the last 2 years, but it's considered cured and low risk of coming back.I have small brain tumors (≤1 cm) that need treatment.I am fully active or can carry out light work.My cancer is advanced, cannot be surgically removed, and I've had standard treatment.
Research Study Groups:
This trial has the following groups:- Group 1: CX-904
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still openings for participants to join this research initiative?
"The clinicaltrials.gov webpage reveals that this experiment is actively seeking participants, having been posted in February of 2022 and subsequently edited in May of the same year."
Answered by AI
How many volunteers are included in this research study?
"Affirmative. Per the information hosted on clinicaltrials.gov, this experiment is currently enrolling patients. It was initially posted in February 22nd 2022 and has recently been amended - as of May 19th 2022 - to incorporate 100 participants across a single site."
Answered by AI
Share this study with friends
Copy Link
Messenger